- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07884448
PliaFX Flo Subtalar Fusion Study
A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada
During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.
This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Tidig fas 1
Kontakter och platser
Studiekontakt
- Namn: Biraj Bora
- Telefonnummer: 604-813-0889
- E-post: biraj.bora@phc.ca
Studieorter
-
-
British Colombia
-
Vancouver, British Colombia, Kanada, V6Z 1Y6
- St. Paul's Hospital
-
Kontakt:
- Biraj Bora
- Telefonnummer: 604-813-0889
- E-post: biraj.bora@phc.ca
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- The subject is at least 19 years of age.
- The subject is considered to be skeletally mature.
- The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
- The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
- The patient may undergo a subtalar fusion as part of a triple arthrodesis.
- The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
- The patient consented for either an arthroscopic or open procedure.
- The subject is able to comply with all post-operative evaluations and visits.
- The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery
Exclusion Criteria:
-
The subject has:
- Severe osteoporosis
- Neuromuscular impairment
- Prior infection in the affected joint
-
The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.
-
The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).
-
The subject is renal compromised.
-
The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).
-
The subject is undergoing a revision of a prior subtalar fusion.
-
The subject has had a prior ankle joint fusion.
-
An ankle joint replacement or ankle joint fusion may be performed during the same sitting.
-
The subject has a BMI of > 50 kg/m2.
-
The subject is known to be pregnant, or plans to become pregnant during the study period
-
The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).
-
The subject is unable to provide informed consent.
-
The subject is unable to communicate with the research team.
-
The subject is unable to comply with follow-up.
-
The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry
-
The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Enhetens genomförbarhet
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: PliaFX Flo Allograft
Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure. |
Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure. |
|
Inget ingripande: No Graft
Participant will receive no graft during their Subtalar Arthrodesis procedure. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Bone Bridging Percentage
Tidsram: Enrollment to last Follow-up visit (52 weeks)
|
Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively. |
Enrollment to last Follow-up visit (52 weeks)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Foot and Ankle Measure (FAAM) Questionnaire
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Current Health Assessment Questionnaire
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Demographics Questionnaire
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
|
|
Ankle Osteoarthritis Scale
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 1, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
SF-36 Health Survey
Tidsram: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- H26-01617
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .